

Supplementary Table S1. The effects of gene-gene interactions in homozygous model on the survival of gastric cancer patients receiving platinum-based chemotherapy

combined genotypes	patient	death	MST	P	HR (95%CI) ^a
<i>FAS 1377 G> A and FAS 670 A> G</i>					
<i>FAS 1377 GG + FAS 670 AA</i>	208	96		0.790	1
<i>FAS 1377 GG + FAS 670 GG</i>	2	1			1.398(0.195-10.036)
<i>FAS 1377AA + FAS 670 AA</i>	1	0			0
<i>FAS 1377AA + FAS 670 GG</i>	51	24			1.112(0.711-1.741)
<i>FAS 1377 G> A and FASL 844 C> T</i>					
<i>FAS 1377 GG + FASL 844CC</i>	30	11		0.074	1
<i>FAS 1377 GG + FASL 844TT</i>	16	6			0.691(0.252-1.900)
<i>FAS 1377AA + FASL 844CC</i>	9	6			2.508(0.922-6.823)
<i>FAS 1377AA + FASL 844TT</i>	2	0			0
<i>FAS 1377 G> A and CASP8 6526 ins > del</i>					
<i>FAS 1377 GG + CASP8 6526 II</i>	73	26	68 ^b	0.434	1
<i>FAS 1377 GG + CASP8 6526 DD</i>	6	1	87 ^b		0.378(0.051-2.788)
<i>FAS 1377AA + CASP8 6526 II</i>	12	6	30		1.691(0.693-4.127)
<i>FAS 1377AA + CASP8 6526 DD</i>	2	1	18		1.470(0.199-10.863)
<i>FAS 670 A> G and FASL 844 C> T</i>					
<i>FAS 670AA + FASL 844CC</i>	23	9	55 ^b	0.218	1
<i>FAS 670AA + FASL 844TT</i>	13	4	62 ^b		0.526(0.160-1.730)
<i>FAS 670GG + FASL 844CC</i>	13	8	19		1.737(0.668-4.520)
<i>FAS 670GG + FASL 844TT</i>	3	1	36		0.688(0.087-5.456)
<i>FAS 670 A> G and CASP8 6526 ins > del</i>					
<i>FAS 670AA + CASP8 6526 II</i>	65	23	68 ^b	0.622	1
<i>FAS 670AA + CASP8 6526 DD</i>	5	1	87 ^b		0.430(0.058-3.192)
<i>FAS 670GG + CASP8 6526 II</i>	19	9	55		1.384(0.640-2.993)
<i>FAS 670GG + CASP8 6526 DD</i>	2	1	18		1.553(0.209-11.549)
<i>FASL 844 C> T and CASP8 6526 ins > del</i>					
<i>FASL 844CC + CASP8 6526 II</i>	40	19		0.477	1

<i>FASL 844CC + CASP8 6526 DD</i>	4	2			1.025(0.238-4.410)
<i>FASL 844TT + CASP8 6526 II</i>	19	8			0.635(0.276-1.460)
<i>FASL 844TT + CASP8 6526 DD</i>	2	0			0

^aAdjusted for age and sex.

^bMean survival time was provided when MST could not be calculated.

Supplementary table S2. The effects of gene-gene interactions in heterozygous model on the survival of gastric cancer patients receiving platinum-based chemotherapy

combined genotypes	patient	death	MST	P	HR (95%CI) ^a
<i>FAS 1377 G> A and FAS 670 A> G</i>					
<i>FAS 1377 GG + FAS 670 AA</i>	93	33	69 ^b	<0.001	1
<i>FAS 1377 GG + FAS 670 GA</i>	19	7	50 ^b		1.128(0.499-2.552)
<i>FAS 1377GA + FAS 670 AA</i>	1	1	5		40.84(4.925-338.6)
<i>FAS 1377GA + FAS 670 GA</i>	96	51	43		1.830(1.179-2.840)
<i>AS 1377 G> A and FASL 844 C> T</i>					
<i>FAS 1377 GG + FASL 844CC</i>	30	11	57 ^b	0.049	1
<i>FAS 1377 GG + FASL 844TC</i>	63	22	70 ^b		0.762(0.368-1.579)
<i>FAS 1377 GA + FASL 844CC</i>	31	14	36 ^b		1.357(0.616-2.990)
<i>FAS 1377 GA + FASL 844TC</i>	68	40	35		1.533(0.786-2.993)
<i>FAS 1377 G> A and CASP8 6526 ins > del</i>					
<i>FAS 1377 GG + CASP8 6526 II</i>	73	26	68 ^b	0.037	1
<i>FAS 1377 GG + CASP8 6526 DI</i>	32	12	56 ^b		1.036(0.523-2.053)
<i>FAS 1377 GA + CASP8 6526 II</i>	66	38	43		1.918(1.164-3.162)
<i>FAS 1377 GA + CASP8 6526 DI</i>	39	19	33		1.627(0.899-2.945)
<i>FAS 670 A> G and FASL 844 C> T</i>					
<i>FAS 670AA + FASL 844CC</i>	23	9	55 ^b	0.185	1
<i>FAS 670AA + FASL 844TC</i>	56	21	68 ^b		0.778(0.355-1.705)
<i>FAS 670GA + FASL 844CC</i>	34	14	32 ^b		1.156(0.500-2.673)
<i>FAS 670GA+ FASL 844TC</i>	69	39	35		1.384(0.670-2.860)
<i>FAS 670 A> G and CASP8 6526 ins > del</i>					
<i>FAS 670AA + CASP8 6526 II</i>	65	23	68 ^b	0.075	1
<i>FAS 670AA + CASP8 6526 DI</i>	22	9	54 ^b		1.148(0.531-2.481)
<i>FAS 670GA+ CASP8 6526 II</i>	68	38	43		1.904(1.133-3.198)
<i>FAS 670GA + CASP8 6526 DI</i>	42	20	51 ^b		1.593(0.873-2.907)
<i>FASL 844 C> T and CASP8 6526 ins > del</i>					
<i>FASL 844CC + CASP8 6526 II</i>	40	19	49 ^b	0.803	1

<i>FASL 844CC + CASP8 6526 DI</i>	25	9	33 ^b		0.733(0.331-1.621)
<i>FASL 844TC + CASP8 6526 II</i>	89	43	52		0.842(0.490-1.448)
<i>FASL 844TC + CASP8 6526 DI</i>	44	24	30		0.984(0.538-1.799)

^aAdjusted for age and sex.

^bMean survival time was provided when MST could not be calculated.

Supplementary Table S3. The effects of gene-gene interactions in dominant model on the survival of gastric cancer patients receiving platinum-based chemotherapy

combined genotypes	patient	death	MST	<i>P</i>	HR (95%CI) ^a
<i>FAS 1377 G> A and FAS 670 A> G</i>					
<i>FAS 1377 GG + FAS 670 AA</i>	93	33	69 ^b	<0.001	1
<i>FAS 1377 GG + FAS 670 GA+GG</i>	19	7	50 ^b		1.132(0.501-2.559)
<i>FAS 1377 GA+AA + FAS 670 AA</i>	1	1	5		39.245(4.86-316.6)
<i>FAS 1377 GA+AA + FAS 670 GA+GG</i>	135	71	43		1.808(1.195-2.737)
<i>AS 1377 G> A and FASL 844 C> T</i>					
<i>FAS 1377 GG + FASL 844CC</i>	30	11	57 ^b	0.012	1
<i>FAS 1377 GG + FASL 844TC+TT</i>	79	28	70		0.734(0.364-1.480)
<i>FAS 1377 GA+AA + FASL 844CC</i>	40	20	23		1.568(0.751-3.274)
<i>FAS 1377 GA+AA + FASL 844 TC+TT</i>	94	53	36		1.449(0.765-2.777)
<i>FAS 1377 G> A and CASP8 6526 ins > del</i>					
<i>FAS 1377 GG + CASP8 6526 II</i>	73	26	68 ^b	0.012	1
<i>FAS 1377 GG + CASP8 6526 DD+DI</i>	38	13	71 ^b		0.912(0.469-1.775)
<i>FAS 1377 GA+AA + CASP8 6526 II</i>	78	44	43		1.889(1.162-3.070)
<i>FAS 1377 GA+AA + CASP8 6526 DD+DI</i>	57	29	33		1.757(1.033-2.990)
<i>FAS 670 A> G and FASL 844 C> T</i>					
<i>FAS 670AA + FASL 844CC</i>	23	9	55 ^b	0.068	1
<i>FAS 670 AA + FASL 844TC+TT</i>	69	25	70 ^b		0.704(0.328-1.513)
<i>FAS 670 GA+GG + FASL 844CC</i>	47	22	35 ^b		1.322(0.608-2.873)
<i>FAS 670 GA+GG + FASL 844 TC+TT</i>	105	57	39		1.263(0.625-2.554)
<i>FAS 670 A> G and CASP8 6526 ins > del</i>					
<i>FAS 670AA + CASP8 6526 II</i>	65	23	68 ^b	0.059	1
<i>FAS 670AA + CASP8 6526 DD+DI</i>	27	10	70 ^b		0.984(0.468-2.068)
<i>FAS 670 GA+GG + CASP8 6526 II</i>	87	47	43		1.790(1.086-2.950)
<i>FAS 670 GA+GG + CASP8 6526 DD+DI</i>	65	31	37		1.630(0.948-2.801)
<i>FASL 844 C> T and CASP8 6526 ins > del</i>					
<i>FASL 844CC + CASP8 6526 II</i>	40	19	49 ^b	0.833	1

<i>FASL 844CC + CASP8 6526 DD+DI</i>	29	11	32 ^b		0.782(0.372-1.644)
<i>FASL 844 TC+TT + CASP8 6526 II</i>	108	51	52		0.785(0.463-1.333)
<i>FASL 844 TC+TT + CASP8 6526 DD+DI</i>	61	30	51		0.824(0.463-1.466)

^aAdjusted for age and sex.

^bMean survival time was provided when MST could not be calculated.

Supplementary Table S4. Primers for the genotyping assays of Fas,
FasL, CASP8

Genotypes	Forward primer	Reverse primer	Extension primer
FAS rs2234767 1377 G > A	TTTTGTGTCTATTAGATG CTCAGAGTGTGTG	gactgtagtgccatgaggAAGACC	TTTTTTTTTCCATGAGGA AGACCCTGGG
FAS rs1800682 670 A > G	TTGTGGCTGCAACATGAG AGG	TGGCGCAACATCTGTACTTT TTCA	TTTTTTTTTTTTTTTTTCAT GAGAGGCTCACRGACG TT
FASL rs763110 C > T	taaataaaCTGGGCAAACAAT GAAAATG	AAACCAGTGGAACCCACAG AGC	TTTTTTTTTTTTTTTTTTTT TTTTTTTTTTTGCAAACAA TGAAAATGAAAACATTG
CASP8 -652 6N ins > del	ccgaggaaggcactgagacg	GCTTAWAAAGCCATAGTaattc ttgctctgc	